DEDHAM, Mass. — For 11 years, Robert K. Coughlin has been the public face of his state’s booming biotech industry, trumpeting its breakthrough drugs and defending their often-dizzying price tags.
As president of the Massachusetts Biotechnology Council trade group, he lobbies for firms that have marketed life-saving medicines for devastating blood cancers, a rare inherited muscle-wasting disorder, and many other terrible diseases.
